China SXT Pharmaceuticals (SXTC) Equity Average (2019 - 2025)
China SXT Pharmaceuticals (SXTC) has 7 years of Equity Average data on record, last reported at $14.7 million in Q1 2025.
- For Q1 2025, Equity Average rose 2.62% year-over-year to $14.7 million; the TTM value through Mar 2025 reached $14.7 million, up 2.62%, while the annual FY2025 figure was $14.7 million, 2.62% up from the prior year.
- Equity Average reached $14.7 million in Q1 2025 per SXTC's latest filing, up from $14.3 million in the prior quarter.
- Across five years, Equity Average topped out at $16.0 million in Q1 2022 and bottomed at $12.7 million in Q1 2021.
- Average Equity Average over 5 years is $14.6 million, with a median of $14.7 million recorded in 2025.
- Peak YoY movement for Equity Average: increased 26.34% in 2022, then decreased 6.99% in 2024.
- A 5-year view of Equity Average shows it stood at $12.7 million in 2021, then grew by 26.34% to $16.0 million in 2022, then decreased by 3.96% to $15.4 million in 2023, then fell by 6.99% to $14.3 million in 2024, then grew by 2.62% to $14.7 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $14.7 million in Q1 2025, $14.3 million in Q1 2024, and $15.4 million in Q1 2023.